Regulator of G protein signalling 18 promotes osteocyte proliferation by activating the extracellular signal‑regulated kinase signalling pathway

• Published in: International journal of molecular medicine Vol. 53; no. 3; p. 1
• Main Authors: Meng, Yong, Qiu, Si-Qiang, Wang, Qiang, Zuo, Jin-Liang
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.03.2024; Spandidos Publications UK Ltd
• Subjects: Analysis; Apoptosis; Bioinformatics; Biotechnology; Cell cycle; Flow cytometry; Fractures; G proteins; Gene expression; Genes; Joint and ligament injuries; Kinases; Life sciences; Penicillin; Proteins; Scientific equipment and supplies industry; United States; osteocytes; extracellular signal‑regulated kinase signalling; proliferation; regulator of G protein signalling 18; bone fracture
• DOI: 10.3892/ijmm.2024.5346
• ISSN: 1107-3756

Osteocyte function is critical for metabolism, remodelling and regeneration of bone tissue. In the present study, the roles of regulator of G protein signalling 18 (RGS18) were assessed in the regulation of osteocyte proliferation and bone formation. Target genes and signalling pathways were screened using the Gene Expression Omnibus (GEO) database and Gene Set Enrichment Analysis (GSEA). The function of RGS18 and the associated mechanisms were analysed by Cell Counting Kit 8 assay, 5‑ethynyl‑2'‑deoxyuridine assay, flow cytometry, reverse transcription‑quantitative PCR, western blotting and immunostaining. Overlap analysis of acutely injured subjects (AIS) and healthy volunteers (HVs) from the GSE93138 and GSE93215 datasets of the GEO database identified four genes: , , and . Notably, was more highly expressed in peripheral blood samples from AIS than in those from HVs. Furthermore, overexpression promoted MLO‑Y4 and MC3T3‑E1 cell viability, proliferation and S‑phase arrest, but inhibited apoptosis by suppressing caspase‑3/9 cleavage. Silencing exerted the opposite effects. GSEA of GSE93138 revealed that RGS18 has the ability to regulate MAPK signalling. Treatment with the MEK1/2 inhibitor PD98059 reversed the overexpression‑induced osteocyte proliferation, and treatment with the ERK1/2 activator 12‑O‑tetradecanoylphorbol‑13‑acetate reversed the effects of RGS18 silencing on osteocyte proliferation. In conclusion, RGS18 may contribute to osteocyte proliferation and bone fracture healing via activation of ERK signalling.